Prue Cormie1, Nigel Spry, Kevin Jasas, Mikael Johansson, Ian F Yusoff, Robert U Newton, Daniel A Galvão. 1. 1Edith Cowan University Health and Wellness Institute, Edith Cowan University, Joondalup, AUSTRALIA; 2Department of Radiation Oncology, Sir Charles Gairdner Hospital, Nedlands, AUSTRALIA; 3Faculty of Medicine, University of Western Australia, AUSTRALIA; 4Department of Medical Oncology, Sir Charles Gairdner Hospital, Nedlands, AUSTRALIA; 5Department of General Surgery, Sir Charles Gairdner Hospital, Nedlands, AUSTRALIA; 6Department of Gastroenterology, Sir Charles Gairdner Hospital, Nedlands, AUSTRALIA.
Abstract
INTRODUCTION: Given the poor prognosis for patients diagnosed with pancreatic cancer, therapies that enhance the ability to tolerate adjuvant treatments, reduce the loss of physical functioning and optimize quality of life are critically important. Exercise may represent such a therapy; however, no previous research has investigated the potential impact of exercise on outcomes in pancreatic cancer patients. PURPOSE: This study aimed to determine the safety and efficacy of a 6-month supervised exercise program in a pancreatic cancer patient undergoing adjuvant treatment. METHODS: A case study was performed on a 49-yr-old male diagnosed with stage IIb pancreatic cancer. The patient had surgery (Whipple resection) followed by adjuvant chemotherapy (gemcitabine and fluorouracil) and radiotherapy (45 Gy). The patient initiated a supervised exercise program involving twice weekly resistance and aerobic exercise sessions during adjuvant therapy. Outcomes were assessed at baseline and after 3 and 6 months of exercise. RESULTS: The exercise program was well tolerated with 73% attendance throughout the 6 months. No treatment toxicities prevented the patient from complying with adjuvant treatment plans. Considerable improvements were observed at both 3- and 6-month assessment points for all measures of physical capacity and functional ability, lean mass, physical activity levels, general health and disease-specific quality of life, cancer-related fatigue, sleep quality, and psychological distress. CONCLUSIONS: In this first reported clinical case, exercise led to improvements in a variety of patient outcomes during adjuvant therapy for pancreatic cancer. This initial evidence has important clinical implications, indicating that exercise may be an effective adjunct therapy for the management of pancreatic cancer. Future trials are needed to confirm and expand our initial findings.
INTRODUCTION: Given the poor prognosis for patients diagnosed with pancreatic cancer, therapies that enhance the ability to tolerate adjuvant treatments, reduce the loss of physical functioning and optimize quality of life are critically important. Exercise may represent such a therapy; however, no previous research has investigated the potential impact of exercise on outcomes in pancreatic cancerpatients. PURPOSE: This study aimed to determine the safety and efficacy of a 6-month supervised exercise program in a pancreatic cancerpatient undergoing adjuvant treatment. METHODS: A case study was performed on a 49-yr-old male diagnosed with stage IIb pancreatic cancer. The patient had surgery (Whipple resection) followed by adjuvant chemotherapy (gemcitabine and fluorouracil) and radiotherapy (45 Gy). The patient initiated a supervised exercise program involving twice weekly resistance and aerobic exercise sessions during adjuvant therapy. Outcomes were assessed at baseline and after 3 and 6 months of exercise. RESULTS: The exercise program was well tolerated with 73% attendance throughout the 6 months. No treatment toxicities prevented the patient from complying with adjuvant treatment plans. Considerable improvements were observed at both 3- and 6-month assessment points for all measures of physical capacity and functional ability, lean mass, physical activity levels, general health and disease-specific quality of life, cancer-related fatigue, sleep quality, and psychological distress. CONCLUSIONS: In this first reported clinical case, exercise led to improvements in a variety of patient outcomes during adjuvant therapy for pancreatic cancer. This initial evidence has important clinical implications, indicating that exercise may be an effective adjunct therapy for the management of pancreatic cancer. Future trials are needed to confirm and expand our initial findings.
Authors: Gregory T Levin; Kenneth M Greenwood; Favil Singh; Daphne Tsoi; Robert U Newton Journal: Integr Cancer Ther Date: 2015-08-14 Impact factor: 3.279
Authors: Hao Luo; Daniel A Galvão; Robert U Newton; Pedro Lopez; Colin Tang; Ciaran M Fairman; Nigel Spry; Dennis R Taaffe Journal: Pancreas Date: 2021-03-01 Impact factor: 3.243
Authors: Elisabeth S Gruber; Gerd Jomrich; Dietmar Tamandl; Michael Gnant; Martin Schindl; Klaus Sahora Journal: PLoS One Date: 2019-05-06 Impact factor: 3.240